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Abstract
Background: Malignant melanoma is one of the most aggressive skin cancer and chemotherapeutic agents
currently in use are still unsatisfactory. Prevention and early diagnosis are the only effective tools against this
tumour whose incidence and mortality rates are highly increased during the last decades in fair skin populations.
Therefore the search for novel therapeutic approaches is warranted. Aim of this work was to identify and test
new compounds with antiproliferative and cytotoxic activity on melanoma cells. We tested eugenol together with
six natural and synthetic eugenol-related compounds for their capability to inhibit cell growth on primary
melanoma cell lines established from patients' tissue samples.
Results: Eugenol and isoeugenol monomers and their respective O-methylated forms did not show to inhibit
melanoma cells proliferation. Conversely, the dimeric forms (biphenyls) showed some antiproliferative activity
which was mild for dehydrodieugenol, higher for its O,O'-methylated form (O,O'-dimethyl-dehydrodieugenol), and
markedly pronounced for the racemic mixture of the brominated biphenyl (6,6'-dibromo-dehydrodieugenol) (S7),
being its enantiomeric form (S) the most effective compared to the other compounds. Such activity resulted to
be selective against tumour cells, without affecting cultured normal human skin fibroblasts. Dose and time
dependence curves have been obtained for the enantiomeric form S7-(S). Then IC50 and minimal effective doses
and times have been established for the melanoma cell lines tested. TUNEL and phosphatidylserine exposure
assays demonstrated the occurrence of apoptotic events associated with the antiproliferative activity of S7-(S).
Cytotoxic activity and apoptosis induced by treating melanoma cells with eugenol-related biphenyls was partially
dependent by caspase activation.
Conclusion: Our findings demonstrate that the eugenol related biphenyl (S)-6,6'-dibromo-dehydrodieugenol
elicits specific antiproliferative activity on neuroectodermal tumour cells partially triggering apoptosis and its
activity should be further investigated on in vivo melanoma models in order to evaluate the real anticancer
effectiveness on such tumour.
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Background
Malignant melanoma arises from the malignant transfor-
mation of epidermal melanocytes due to both environ-
mental and genetic factors [1,2]. Melanoma is the most
rapidly increasing malignancy in the white population [3]
and, at the present, prevention and early detection repre-
sent the only effective approach to reduce its incidence.
Little progress has been made in medical treatment of
melanoma because of the absence of effective systemic
therapies. Chemotherapy is not giving significant benefits
and it is often associated to severe toxicity [4], while
immunotherapy and vaccines are promising but still inef-
fective [5]. Patients with metastatic melanoma present a
median survival of 4–10 months, depending on the
involvement of the anatomic site (patients with disease
confined to skin or lymph nodes have an overall survival
longer than those with visceral involvement) [6].
It is therefore of primary interest to search for new thera-
peutic agents able to contrast this aggressive tumour. One
of the developing strategies is to test some naturally occur-
ring compounds whose chemopreventive properties in
cancer therapy are already known [7].
Eugenol is a natural phenolic compound that is the main
component of clove oil and it is present in reasonable
amounts in several other spices like basil, cinnamon and
bay leaves. It is used as antiseptic, analgesic and anti-bac-
terial agent in traditional medicine in Asia as well as in
dentistry as main ingredient of cavity filling cement. Sev-
eral biological activities of eugenol have been described in
literature [8,9] and it has been proved not to be carcino-
genic neither mutagenic [10,11]. It possesses antiviral
activity in vitro and in vivo against human herpesvirus [12].
Recently, eugenol was found to induce apoptosis in mast
cells [13], melanoma cells [14] and HL-60 leukemia cells
[15]. Moreover, it has been reported that dimers of euge-
nol related compounds have a better antioxidant activity
than the original monomers [16-18] and that bis-eugenol
shows stronger apoptotic activity than eugenol on leuke-
mic cells [15]. Dimers of eugenol related compounds are
hydroxylated biphenyls such as magnolol and honokiol,
being the latters the main constituents of the stem bark of
Magnolia officinalis, whose biological properties are well
known in literature. Indeed, they both have antioxidant
and antidepressant properties [19,20] and recent reports
have demonstrated that honokiol have antiangiogenic
and antitumoural activity inducing apoptosis [21,22].
On this basis, we screened a panel of eugenol related com-
pounds in order to verify their possible ability to interfere
with melanoma cells growth, as a first step toward the
development of new therapeutic drug. We decided to
compare eugenol and six related compounds differing for
structure (monomeric or dimeric), chemical groups
(hydroxylated,  O-methylated and/or brominated) and
specific conformational structure [(S) or (R) enantiomeric
forms] for antitumour capability. We demonstrated that
the byphenyl structure, the presence of bromine substitu-
tion and a specific stereo configuration of the molecule
are important for the antiproliferative activity and induc-
tion of apoptotic cell death on melanoma cell lines.
Results
Effect of eugenol derivatives (S1–S7) on the proliferation 
of melanoma cell lines
Cell proliferation assays were performed to test the possi-
ble cytotoxicity of eugenol related compounds. As a first
screening, nine melanoma cell lines (see Methods section
for cell lines details) were grown up to 6 days in the pres-
ence of 100 μM of each of the seven compounds S1 to S7,
listed in Figure 1. None of the nine melanoma cell lines
was inhibited by the treatment of 100 μM eugenol (S1) or
isoeugenol (S2) (Figure 2). As shown in Figure 2A,
methyl-eugenol (S3) and methyl-isoeugenol (S4) treat-
ments slightly inhibited melanoma cells growth (of about
20–40%). Dimeric forms were more effective. In particu-
lar, dehydrodieugenol (S5) decreased cell growth rate of
about 40–60%, O,O'-dimethyl-dehydrodieugenol (S6)
caused a consistent growth inhibition of about 70–80%,
whereas the 6,6'-dibromo-dehydrodieugenol (S7)
induced a quite complete growth inhibition (about
100%) in all the nine melanoma cell lines (Figure 2A).
Treatment with the latter compound showed an efficacy
on cell proliferation better than the administration of 5
μM cisplatinum, a chemotherapeutic drug known as
potent cytotoxic agent on cancer cell lines. On the basis of
these results we decided to further investigate on the anti-
proliferative activity of compounds S3 to S7.
Dose dependence of S3–S7
Proliferation assays were then performed using three dif-
ferent concentrations of the eugenol-related compounds
showing cytotoxic activity. Formerly, melanoma cell lines
were treated with 100, 10, and 1 μM of each S3–S7 and
proliferation rates were evaluated after 6 days as described
in the Materials and Methods section (Figure 2B). Cell
growth inhibition at 100 μM of these compounds some-
how reproduced the data of Figure 2A. At lower concentra-
tion (10 μM) S3, S4, S5, and S6 showed only partially
specific inhibition of melanoma cell growth, while S7
confirmed its activity on all the tested cell lines (most of
them presented a 80% or lower of growth rate, with few,
more sensitive, cell lines, such as GR and 13443, whose
growth rate was around the 50%). None of the com-
pounds tested at 1 μM final concentration showed any sig-
nificant activity. These results suggested that compounds
S3–S6 have a much weaker anti-proliferative effect to be
further tested in in vivo assays. Conversely, our interest has
been focused on the potential biological activity of the S7Molecular Cancer 2007, 6:8 http://www.molecular-cancer.com/content/6/1/8
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dimer. The S7 compound is a chiral molecule (Figure 1)
therefore two atropo-enantiomers are evidenced at room
temperature. Often, the two stereoisomers can show dif-
ferent biological activity, for this reason we decided to test
the activity of both the enantiomers S7-(S) and S7-(R) on
tumour cells.
Enantiopure form S7-(S) is more active than both S7-(R) and their 
racemic mixture
The dose-dependent effects on three melanoma cell lines
(WM, GR, PNP) and on normal fibroblasts short term cul-
ture (as control) were tested using S7 racemic mixture, S7-
(R) and S7-(S). Graphics reported in Figure 3 show that
the S7-(S) enantiomeric form was more active on inhibit-
ing melanoma cell proliferation than the two other forms
and that normal fibroblasts were not affected by these
treatments up to the concentration of 60 μM. IC50 values
for each form of S7 on the melanoma cell lines tested are
reported in Table 1.
To validate the efficacy of S7-(S) as novel putative antican-
cer agent for neuroectoderma-derived tumours, we tested
its anti-proliferative activity also on neuroblastoma (NB)
cells, the pediatric solid tumour sharing with melanoma
the origin from neural crest cells. As reported in Table 1,
S7-(S) was slightly more efficient on NB cells showing
IC50 values less than 20 μM after 5 days of treatments.
Time dependence and anticancer specificity of S7-(S)
Time-course experiments using 50 μM S7-(S) up to 5 days
showed that its anti-proliferative activity was already evi-
dent after 24 hours of treatment (30–60% of growth inhi-
bition), reaching 90–100% of growth inhibition after 3
treatments in the 5th day (Figure 4A).
To simulate the activity of S7-(S) in vivo, we tested the
response of melanoma cells to the drug after very short
exposures. Indeed, wash-out experiments using 50 μM S7-
(S) up to 48 hours better defined the action time window
Chemical structures of eugenol and related compounds Figure 1
Chemical structures of eugenol and related compounds.
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Effect of eugenol derivatives on the growth of human melanoma cell lines Figure 2
Effect of eugenol derivatives on the growth of human melanoma cell lines. Nine melanoma cell lines were cultured 
(A) in presence of 100 μM or (B) with various concentrations of each compound (S1–S7), for 6 days and cell proliferation was 
estimated as described in Material and Methods. Results are expressed as percent of cell growth and represent the average (± 
standard deviation) of triplicate cultures performed twice. 5 μM Cisplatinum was used as cytotoxic agent positive control.
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Dose-dependent S7 antiproliferative activity: comparison of raceme mixture with the enantiopure forms S7-(R) and S7-(S) Figure 3
Dose-dependent S7 antiproliferative activity: comparison of raceme mixture with the enantiopure forms S7-
(R) and S7-(S). Three melanoma cell lines and one short term culture of human fibroblasts were treated with various concen-
trations of S7, S7-(R) and S7-(S) for 3 days. Cell proliferation was estimated as described in Material and Methods. Results are 
expressed as percentage of cell growth and represent the average (± standard deviation) of triplicate cultures performed twice.
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of such compound establishing that a single administra-
tion of S7-(S) is sufficient to inhibit melanoma cell
growth up to 80% for 48 hours with no effect on cell
growth of normal fibroblasts (Figure 4B).
We then examined the effect of S7-(S) on the viability of
cultured melanoma cells by trypan blue staining.
Melanoma cells and fibroblasts were incubated with 50
μM S7-(S) for 24 hours and their viability was assessed.
The results showed a statistically significant cytotoxic
activity of S7-(S) on melanoma cells without affecting
non-transformed cells (Figure 5A). Similar results were
obtained with the other melanoma and NB cell lines (data
not shown).
Effects of S7-(S) on apoptosis in melanoma cell lines
To determine whether the observed S7-(S)-induced reduc-
tion in viability of melanoma cells occurred via induction
of apoptosis, we used TUNEL staining to measure DNA
fragmentation and phosphatidylserine exposure as an
early hallmark of apoptotic cell death in treated cells. As
evidenced in Panels d and e of Figure 5C, a small, but con-
sistent proportion of TUNEL-positive melanoma cells
(15–20% apoptotic fraction) was detected after 24 hours
of treatment with 50 μM S7-(S), while no evidences of
apoptosis were observed in human fibroblasts (Fig. 5C,
panel f). Moreover, the same treatment of melanoma cells
with S7-(S) induced a significant increase in the number
of cells expressing phosphatidylserine on cell surface (Fig-
ure 5B).
Besides nuclear condensation and appearance of oligonu-
cleosomal DNA, induction of apoptosis may involve acti-
vation of aspartate specific cysteine proteases or caspases
[23]. Melanoma cells were treated for 24 hours with 50
μM S7-(S) in the presence or absence of pan-caspase
inhibitor (z-VAD-fmk, 100 μM). Pan-caspase inhibitor
significantly reduced the number of trypan blue-positive
cells (Figure 5A) and significantly blocked S7-(S)-trig-
gered apoptosis (Figure 5B).
Discussion
To verify the possible anti-proliferative effect of some eug-
enol derivatives as a first step toward the development of
novel putative anticancer agents, we tested eugenol and
isoeugenol as well as five eugenol-related compounds for
their capability to inhibit cell growth and viability on a
panel of melanoma cell lines.
Previous report showed that eugenol, but not its isomer
isoeugenol, inhibit melanoma cell proliferation by arrest-
ing cells in the S phase of cell cycle and inducing apoptosis
[14]. Moreover, eugenol and creosol dimers are widely
reported as cytotoxic and antioxidant agents inducing
apoptosis on HL-60 leukemia cells [15,17], with much
stronger effects than their original monomers. We have
previously described the synthesis and purification of the
two enantiopure forms of 6,6'-dibromo-dehydrodieuge-
nol and its antinociceptic activity [24,25]. In the present
study, we demonstrate that this compound, a brominated
dimer of eugenol, is the most potent eugenol-derivative
able to show antiproliferative action on melanoma cells,
partially triggering apoptosis, and it could be considered a
potential candidate to be tested in in vivo models as anti-
cancer agent. Moreover, we show that the enantiopure
form (aS) of such compound is much more active, as anti-
proliferative agent, than both the racemic mixture and the
enantiopure (R) form. This is a frequent property of chiral
compounds whose biological activity is often related to a
defined absolute configuration. Stereo-isomeric forms of
same compound may show very different properties and
bio-activity, like different degree of absorption and clear-
ance, different metabolic pathways and toxicological
characteristics [26]. To date, brominated biphenyls have
been described to have a role in antimicrobial and antivi-
ral therapies [27,28]. Our findings point out the anti-pro-
liferative properties of eugenol related compounds, whose
dimeric forms, conversely from the eugenol monomeric
form (which did not show any activity on inhibiting
melanoma cell growth), are able to block tumour cell
growth. Indeed, none of the nine melanoma cell lines
Table 1: IC50 for S7, S7-(R) and S7-(S)
IC50 [μM]
Cell lines S7 raceme S7-(R)S 7 - ( S)
WM (MM) 38,5 36 27
GR (MM) 30,0 31,5 23
PNP (MM) 46,0 41 29
GILIN (NB) n.d. n.d. 19
LAN-5 (NB) n.d. n.d. 16
Legend: MM (Malignant Melanoma)
NB (Neuroblastoma)
n.d. (not done)Molecular Cancer 2007, 6:8 http://www.molecular-cancer.com/content/6/1/8
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Time-dependent antiproliferative effect of S7-(S) on melanoma cells Figure 4
Time-dependent antiproliferative effect of S7-(S) on melanoma cells. (A) Eight melanoma cell lines were treated 
with 50 μM S7-(S) and cell proliferation was estimated at the different points, as described in Material and Methods. Results are 
expressed as percentage of cell growth and represent the average (± standard deviation) of triplicate cultures performed twice. 
(B) S7-(S) wash-out assay. Three melanoma cell lines and one short term culture of human fibroblasts were treated with 50 
μM S7-(S) for various times (6–12–18–24–48 hours), then washed and incubated with S7-(S) free medium. Cell proliferation 
was estimated 48 hours after initiation of treatment, as described in Material and Methods. Results are expressed as percent-
age of cell growth and represent the average (± standard deviation) of triplicate cultures performed twice.
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Effect of S7-(S) on cell viability and apoptosis in melanoma cells Figure 5
Effect of S7-(S) on cell viability and apoptosis in melanoma cells. (A) Melanoma cells and normal fibroblasts were 
incubated with 50 μM S7-(S) or solvent (control) for 24 hours, and cell death was determined by trypan blue staining. Results 
are expressed as mean number of trypan blue-positive cells in triplicate cultures from two independent experiments. Cells 
were also pre-treated for 1 hour with the pan-caspase inhibitor before S7-(S) treatment. P values for S7-(S) versus control and 
for inhibitor versus S7-(S) were calculated by Student's t-test with Welch correction: *, P < .05; **, P < .01. (B) Effect of S7-(S) 
on phosphatidylserine exposure on melanoma cells. Human fibroblasts and melanoma cell lines were incubated in the presence 
or absence of 50 μM S7-(S) for 24 hours. Cells were also pre-treated for 1 hour with the pan-caspase inhibitor before S7-(S) 
treatment. Cells were double stained with annexin V-FITC to detect phosphatidylserine exposure and propidium iodide to 
detect DNA and analysed by flow cytometry. Results are expressed as mean percentage of apoptotic cells from three inde-
pendent experiments. P values for S7-(S) versus control and for inhibitor versus S7-(S) were calculated by Student's t-test with 
Welch correction: *, P < .05; **, P < .01; ***, P < .001. (C) Effect of S7-(S) on DNA fragmentation in melanoma cells. GR-mel 
(a, d), Sbcl2 (b, e) melanoma cell lines and human fibroblasts (c, f) were treated with 50 μM (d, e, f) S7-(S) or grown in S7-(S) 
free medium (control a, b, c) for 24 hours and apoptotic cells (red) were stained by the TUNEL assay. Cell nuclei (blue) were 
stained with DAPI.
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(including Sbcl2 cell line used by Ghosh and collabora-
tors [14]) was inhibited by treatment with 100 μM euge-
nol (S1) and isoeugenol (S2) (see Figure 2). This
contrasting data could be due to the different culture con-
ditions used in the laboratories. In our experiments, the
anti-tumour capability notably increased in the methyl-
ated and brominated dimeric forms of eugenol, which
indeed show better cytotoxic activity than the monomeric
forms. The importance of the dimeric structure is also
shown by other compounds of natural origin, such as the
hydroxylated biphenyls magnolol and honokiol, whose
biological properties are well known in literature
(honokiol has been proven to be a potent anti-angiogenic
and anti-tumoural compound inducing apoptosis
[21,22]).
Moreover, the S7-(S) compound seems to have a quite
specific activity on tumour cells, since it is not toxic to nor-
mal human diploid fibroblasts when used at the same
conditions that completely arrest melanoma cells growth
and induced cell death. Wash-out experiments were per-
formed to reproduce in vivo like conditions, treating cells
with a single dose of the compound to be tested, and
washing it out after increasing time intervals, in order to
mimic drug processing and clearance occurring in tumour
tissue [29]. Such experiments demonstrated that a single
dose of 50 μM S7-(S) drastically inhibits melanoma cell
growth up to 80% after 48 hours of treatment without
affecting cell growth in normal cells (see Figure 4B).
We finally addressed the question whether inhibition of
cell proliferation and induction of cell death in
melanoma cells by S7-(S) is mediated by apoptosis.
Although, our findings strongly suggest a pivotal role of
caspases in S7-(S)-triggered apoptosis, further studies will
better clarify the role of upstream signals – between drug
exposure and caspase activation – or the involvement of
cell death mechanisms other than apoptosis, such as
autophagy and mitotic catastrophe [30,31].
Conclusion
In conclusion this work demonstrates that the biphenyl
eugenol-derivative enantiomer (S)-6,6'-dibromo-dehydr-
odieugenol, is an effective cytotoxic agent for melanoma
and neuroblastoma cells and it is endowed with apoptotic
inducing capability. Moreover its action is selective on
tumour cells not interfering with normal cells growth.
Our data support the effectiveness of biphenyl as dimeric
structures with specific substitute and stereo configuration
in inhibiting the malignant proliferation of neuroectoder-
mal tumour cells in vitro. Further investigation of S7-(S) in
mouse cancer models will contribute to better understand
its in vivo activity against malignant cells and its real toxic-
ity in normal tissues. Assessment of the molecular mech-
anism underlying the activity of this compound as well as
biological test of similar substances to be active at lower
concentration will represent the aims of future research
efforts.
Methods
Cell lines
Malignant melanoma cell lines WM266-4 (WM), SK-Mel-
28 (SK), LCP-Mel (LCP), LCM-Mel (LCM), PNP-Mel
(PNP), CN-MelA (CN), 13443, GR-Mel (GR) were kindly
provided by Drs. D. Castiglia and S. D'Atri at the Institute
"Dermopatico dell'Immacolata" in Rome. They were
established as primary short term cell cultures starting
from tumour samples of donors patients with docu-
mented diagnosis of malignant melanoma after obtaining
their informed consent, as previously described [32].
SbCl2 melanoma cell line [33] and the human Neuroblas-
toma (NB) cell lines, GI-LI-N [34] and LAN-5 [35], were
used between passages 50 and 75.
Short term cultures of normal human fibroblasts from
healthy donors were established at National Cancer Insti-
tute in Naples and at Gaslini Children's hospital and used
as controls.
Cells were cultured to confluence in tissue culture flasks
using either Dulbecco's minimal essential medium
(DMEM) or RPMI medium (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS and penicillin/streptomycin
[100 IU (50 μg)/ml] in a humidified 5% CO2 atmosphere
at 37°C, as previously described [36,37,33].
Eugenol and derivatives
Eugenol (S1) and isoeugenol (S2) were purchased from
Sigma-Aldrich (St. Louis, MO), purity 99% and 98%
respectively. Isoeugenol was a 90:10 mixture of trans:cis
isomeric forms. Eugenol and isoeugenol derivatives S3–
S7 (Fig. 1) were synthesized at the C.N.R., Bio-molecular
Chemistry Institute in Sassari, as previously described
[24]. S1–S4 were solved in ethanol 99% while S5–S7 in
DMSO, all at a stock dilution of 100 mM, and then used
for cells treatments at concentration between 100 μM and
1 nM in complete medium. Chemical structures and
nomenclature of the compounds used are reported in Fig-
ure 1.
The chemotherapeutic agents Cisplatinum and Etoposide
(Teva Pharma B.V., Holland) were used as cytotoxic posi-
tive controls at concentration of 5 μM and 25 μM, respec-
tively, in complete medium.
Cell proliferation assay
Cells were plated (3 × 103/well) in 96-well plates in their
complete medium. After 24 hours, medium was removed
and replaced on days 1, 3 and 5 in quadruplicate by the
same medium (control) or supplemented with variousMolecular Cancer 2007, 6:8 http://www.molecular-cancer.com/content/6/1/8
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S1–S7 doses as described in legend of figures. Cells were
observed with inverted microscope every 24 hours to
check on morphological changes, suffering or cell death.
The percentage of cell proliferation was estimated on day
6 by the colorimetric assay of Kueng et al. [38] modified
as follows: cells were fixed for 20 min at room tempera-
ture with 4% paraformaldehyde (PFA), stained with 0.1%
crystal violet in 20% methanol for 20 min, washed with
PBS, solubilized with 10% acetic acid and read at 595 nm
in a microplate reader (SpectraFluor Plus, Tecan, Austria).
To assess the impact of drug exposure time on cell prolif-
eration, washout experiments were also performed
according to the method shown by Keshelava et al. [39].
Briefly, S7-(S) containing medium was removed from the
cultures after 6–12–18–24 hours by two PBS washings.
Cells were subsequently covered with fresh drug-free
medium and incubated until 48 hours and cell prolifera-
tion rate was evaluated by the same colorimetric assay.
Cell viability assay
Following the indicated treatments (see legend of Figure
5), cells were incubated with trypan blue, for one minute
at 37°C. Trypan blue-positive and total cells were counted
per microscope field, for a total of four fields for each
combination. The proportion of dead cells was calculated
by dividing the number of dead cells by that of total cells/
field. Alternatively, viable cell number was counted. In
some experiments, cells were cultured for 1 hour with 100
μM Z-VAD-FMK (pan-caspases inhibitor, Sigma Aldrich,
St. Louis, MO) before S7-(S) treatments, and then viabil-
ity was evaluated.
Apoptosis assays
TUNEL assay
Melanoma cells (5 × 104/well) were plated in 8 well-
chamber slides and, after 24 hours of culture, were treated
with S7-(S) (50 μM and 100 μM) or 25 μM Etoposide.
After a further 24 hours, DNA cleavage was assessed by
enzymatic end-labeling of DNA strand breaks using a
commercial kit (In Situ Cell Death Detection Kit, Roche,
Penzberg, Germany), according to the manufacturer's
instructions. Briefly, slides with adherent cells were air-
dried and fixed in 4% PFA for 1 hour at room tempera-
ture, washed in PBS and permeabilized with 0.1% Triton
X-100 and 0.1% sodium citrate for 2 minutes at 4°C; after
rinsing, slides were incubated with 50 μl of TUNEL reac-
tion mixture, containing terminal deoxynucleotidyl trans-
ferase (TdT) and TMR red-labeled dUTP, in a humidified
atmosphere for 1 hour at 37°C in the dark. Rinsed slides
were then dyed with 0.2 μg/ml 4',6'-diamidino-2-phe-
nylindole (DAPI) (Vector Laboratories, Burlingame, CA)
in PBS, for nuclear counterstaining, and then washed
again with PBS. Finally slides were coverslipped with
Mowiol 4–88 mounting medium (Calbiochem, San
Diego, CA). Cells were analyzed under a Olimpus BX 50
fluorescent microscope with appropriate DAPI and TMR
red filter sets. The images were acquired with a high-sensi-
tivity monochrome charge-coupled device (CCD) camera.
Phosphatidylserine detection
Phosphatidylserine (PS) exposure was assessed with a
human Annexin V- fluorescein isothiocyanate (FITC) Kit
(Bender MedSystems, Vienna, Austria). Briefly, cultured
and S7-(S) treated primary melanoma cells were collected,
washed and incubated for 10 minutes with 5 μl Annexin
V-FITC, washed once with PBS, resuspended in 190 μl pre-
diluted binding buffer containing 10 μl of a 20 μg/ml pro-
pidium iodidide (PI) I stock solution and examined by
two colour flow cytometry using a FACScan (Beckton
Dickinson, Franklin Lakes, NJ). FITC and PI fluorescence
intensities were recorded through a 520–530 (FL1-H) and
575 (FL2-H) nm filters, respectively. At least 10,000
events were collected in each dot plot and analyzed using
Cell Quest software (Beckton Dickinson, Franklin Lakes,
NJ). Cells that did not stain for either Annexin V-FITC or
PI were viable and did not undergo measurable apoptosis;
those that stained for Annexin FITC, but not for PI, were
in the early stages of apoptosis; cells that stained positive
for both Annexin V-FITC and PI were either in the late
stages of apoptosis or necrotic, as previously described
[40].
Statistical methods
Results are expressed as mean ± standard deviation. All in
vitro data are from at least three independent experiments.
The statistical significance of differential findings between
experimental groups and controls was determined by Stu-
dent's t-test with Welch correction. These findings were
considered significant if two-tailed P values were < 0.05.
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